GLPwatch
Papers (12034)
Page 89 of 201, ranked by citation count.
- Diabetic Ketoacidosis in a Patient With Type I Diabetes Treated With a Closed-Loop Sensor-Augmented Insulin Infusion System.
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.
- Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
- The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
- Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.
- The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
- Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
- Liraglutide treatment effects on rat ovarian and uterine tissues.
- Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R.
- Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line.
- Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD).
- Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
- Microglial activation and hypothalamic structural plasticity in HFD obesity: insights from semaglutide and minocycline.
- Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures.
- PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
- Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.
- Liraglutide: effects beyond glycaemic control in diabetes treatment.
- No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
- Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.
- Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
- Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
- Semaglutide ameliorates lipopolysaccharide-induced acute lung injury through inhibiting HDAC5-mediated activation of NF-κB signaling pathway.
- Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
- Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.
- Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.
- Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
- Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
- Current pharmacotherapies for obesity: A practical perspective.
- Semaglutide in renal ischemia-reperfusion injury in mice.
- Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.
- Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
- Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
- Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
- Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
- Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
- Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.
- Glycogen synthesis kinase-3β involves in the analgesic effect of liraglutide on diabetic neuropathic pain.
- Overview of new antiobesity drugs.
- Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats: Contribution of cAMP/PKA/p-CREB and M1/M2 Microglia Polarization.
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
- Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
- Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
- Semaglutide for obesity: four STEPs forward, but more to come.
- Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.
- Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
- Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
- Sex Differences in Obesity and Its Treatment.
- Liraglutide suppresses obesity and promotes browning of white fat via miR-27b <i>in vivo</i> and <i>in vitro</i>.
- Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
- 68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.
- Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
- Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.
- Efficacy and safety of liraglutide in Indian adolescents with obesity.
- Wegovy: FDA approves weight loss drug to cut cardiovascular risk.
- Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.
- Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
- Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.
- Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.